Trial Profile
A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men With Osteoporosis Treated With Vitamin D and Calcium
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary) ; Calcium carbonate; Colecalciferol
- Indications Male osteoporosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 17 Feb 2021 Part 2 was removed (protocol amendment 1 year into the study) to minimize the risk of bone loss to patients who would be on placebo during months 24 to 36.
- 01 Jan 2021 Results published in the Osteoporosis International
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.